D.E. Shaw & Co’s Protalix BioTherapeutics PLX Stock Holding History

D.E. Shaw & Co’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-27,460	Closed	-$489K	–	3847
2015 Q1	$489K	Buy	27,460 +9,414	+52%	+$184K	﹤0.01%	3055
2014 Q4	$332K	Buy	18,046 +9,775	+118%	+$210K	﹤0.01%	3595
2014 Q3	$200K	Buy	8,271 +4,715	+133%	+$136K	﹤0.01%	3892
2014 Q2	$130K	Buy	+3,556	New	+$143K	﹤0.01%	4061
2014 Q1	–	Sell	-4,060	Closed	-$158K	–	4537
2013 Q4	$158K	Sell	4,060 -14,245	-78%	-$600K	﹤0.01%	4317
2013 Q3	$829K	Sell	18,305 -724	-4%	-$37.2K	﹤0.01%	3202
2013 Q2	$934K	Buy	+19,029	New	+$1.01M	﹤0.01%	2770

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

D.E. Shaw & Co's PLX Position: Q2 2015 in Review

D.E. Shaw & Co sold out of Protalix BioTherapeutics (PLX) in Q2 2015, closing a stake of 27,460 shares — an estimated $489K sold.

D.E. Shaw & Co first reported a position in PLX in Q2 2013 and held it in 7 quarters. The position peaked at $934K in Q2 2013. 35 funds tracked by Wall St. Rank hold PLX as of Q2 2015.

D.E. Shaw & Co reported no remaining Protalix BioTherapeutics position as of Q2 2015 after selling out during the quarter.
D.E. Shaw & Co sold 27,460 Protalix BioTherapeutics shares in Q2 2015, an estimated $489K.
D.E. Shaw & Co first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 7 quarters.
D.E. Shaw & Co's Protalix BioTherapeutics position peaked at $934K in Q2 2013.
35 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2015.

Based on D.E. Shaw & Co's 13F filing for Q2 2015, filed 14 Aug 2015.